Clement A Meseda

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Third-generation smallpox vaccines: challenges in the absence of clinical smallpox
    Clement A Meseda
    Center for Biologics Evaluation and Research, USFDA, Rockville, MD 20852, USA
    Future Microbiol 5:1367-82. 2010
  2. ncbi Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, HFM 457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
    Clin Vaccine Immunol 16:1261-71. 2009
  3. ncbi Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity
    Yong He
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 196:1026-32. 2007
  4. ncbi Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines
    Alonzo D Garcia
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics and Evaluation and Research FDA, 1401 Rockville Pike, HFM 457, Rockville, MD 20892, USA
    Clin Vaccine Immunol 14:1032-44. 2007
  5. ncbi Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, HFM-457 Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Bethesda, MD 20892, USA
    Virology 339:164-75. 2005
  6. ncbi Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge
    Yong He
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Vaccine 28:699-706. 2010
  7. ncbi Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D
    Clement A Meseda
    Laboratory of DNA Viruses, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20852, USA
    Viral Immunol 19:250-9. 2006
  8. ncbi Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein
    Joan E Adamo
    Laboratory of DNA Viruses, Center for Biologics Evaluation and Research CBER, US Food and Drug Administration FDA, Bethesda, MD 20892, USA
    J Gen Virol 90:2604-8. 2009
  9. ncbi Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs
    Marina Zaitseva
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29B, Room 4NN06, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 85:9147-58. 2011
  10. ncbi Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene
    Majid Laassri
    Center for Biologics Evaluation and Research, US Food and Drug Administration, 1401 Rockville Pike, HFM 470, Rockville, Maryland 20852, USA
    J Med Virol 79:791-802. 2007

Collaborators

Detail Information

Publications14

  1. ncbi Third-generation smallpox vaccines: challenges in the absence of clinical smallpox
    Clement A Meseda
    Center for Biologics Evaluation and Research, USFDA, Rockville, MD 20852, USA
    Future Microbiol 5:1367-82. 2010
    ..Harnessing this information is necessary to assess the effectiveness and potential usefulness of new-generation smallpox vaccines...
  2. ncbi Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, HFM 457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
    Clin Vaccine Immunol 16:1261-71. 2009
    ..Taken together, the results extend our current understanding of the protective immune responses elicited by LC16m8 and indicate that the relative efficacy in a mouse model rivals that of previously licensed smallpox vaccines...
  3. ncbi Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity
    Yong He
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 196:1026-32. 2007
    ..These findings demonstrate that A27 antibodies do not represent the major fraction of neutralizing activity in VIG and suggest that immunity may be augmented by vaccines and immune globulins that include strong antibody responses to A27...
  4. ncbi Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines
    Alonzo D Garcia
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics and Evaluation and Research FDA, 1401 Rockville Pike, HFM 457, Rockville, MD 20892, USA
    Clin Vaccine Immunol 14:1032-44. 2007
    ..The resulting polyclonal antisera were used in Western blot analysis and immunofluorescence assays, indicating that rSFV particles are useful vectors for generating monospecific antisera...
  5. ncbi Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, HFM-457 Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Bethesda, MD 20892, USA
    Virology 339:164-75. 2005
    ..In addition, both Dryvax and various MVA vaccination protocols elicited antibody responses to the extracellular enveloped form of the virus and afforded protection against a lethal intranasal challenge with vaccinia virus WR...
  6. ncbi Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge
    Yong He
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Vaccine 28:699-706. 2010
    ..These findings show that rA27 can synergize with MVA to elicit robust protection that has a dose-sparing effect on MVA and can accelerate protection by eliminating the need for a booster dose...
  7. ncbi Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D
    Clement A Meseda
    Laboratory of DNA Viruses, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20852, USA
    Viral Immunol 19:250-9. 2006
    ..Thus, needle-free delivery of plasmid DNA may provide additional flexibility and options for effective prime-boost vaccination...
  8. ncbi Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein
    Joan E Adamo
    Laboratory of DNA Viruses, Center for Biologics Evaluation and Research CBER, US Food and Drug Administration FDA, Bethesda, MD 20892, USA
    J Gen Virol 90:2604-8. 2009
    ..Mice vaccinated with purified VCP demonstrated a strong humoral response, but were not protected against a moderate lethal challenge of vaccinia virus, suggesting that the humoral response against VCP is not critical for protection...
  9. ncbi Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs
    Marina Zaitseva
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29B, Room 4NN06, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 85:9147-58. 2011
    ....
  10. ncbi Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene
    Majid Laassri
    Center for Biologics Evaluation and Research, US Food and Drug Administration, 1401 Rockville Pike, HFM 470, Rockville, Maryland 20852, USA
    J Med Virol 79:791-802. 2007
    ..Potentially, the proposed method could be used as an identity test and could be extended for the entire viral genome and used to monitor consistency of vaccine production...
  11. ncbi Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin
    Agnes Jones-Trower
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, HFM-457, 1401 Rockville Pike, Rockville, MD 20852-1448, USA
    Virology 343:128-40. 2005
    ..The humoral immune response in immunized mice is qualitatively similar to that in humans...
  12. ncbi DNA immunization with a herpes simplex virus 2 bacterial artificial chromosome
    Clement A Meseda
    Laboratory of DNA Viruses, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Virology 318:420-8. 2004
    ..The results further suggest that such technology will be a powerful tool for dissecting the immune response to HSV-2...
  13. ncbi Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    J Infect Dis 186:1065-73. 2002
    ....
  14. ncbi Vaccinia virus nicking-joining enzyme is encoded by K4L (VACWR035)
    Dawn Eckert
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, HFM-457, 1401 Rockville Pike, Rockville, MD 20852-1448, USA
    J Virol 79:15084-90. 2005
    ..Purification of the K4L FLAG polypeptide expressed in bacteria yielded protein containing nicking-joining activity, implying that K4L is the only vaccinia virus protein required for the nicking-joining enzymatic activity...